Helicobacter pylori infection Medical Services in China

Helicobacter pylori (H. pylori) infection is a chronic bacterial colonization of the gastric mucosa, primarily affecting the stomach and duodenum. First identified in 1982 by Barry Marshall and Robin Warren, this gram-negative, microaerophilic, spiral-shaped bacterium survives the acidic gastric environment by producing urease—an enzyme that hydrolyzes urea into ammonia and carbon dioxide, thereby neutralizing local acidity. Pathogenesis involves bacterial adhesion to gastric epithelial cells via adhesins (e.g., BabA, SabA), induction of inflammation through virulence factors (notably CagA and VacA), disruption of tight junctions, oxidative stress, and progressive mucosal injury. Over time, persistent infection can lead to chronic gastritis, peptic ulcer disease (PUD), gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and is classified by the WHO as a Group I carcinogen due to its strong causal association with gastric adenocarcinoma—accounting for approximately 90% of non-cardia gastric cancers. Epidemiologically, H. pylori infects nearly half the global population, with prevalence exceeding 70% in low- and middle-income countries and ranging from 20–40% in high-income nations. Infection is typically acquired in childhood, often through oral–oral or fecal–oral routes, and clusters within families and crowded living conditions. Key risk factors include poor sanitation, inadequate clean water access, lower socioeconomic status, overcrowded housing, and limited education. While many infected individuals remain asymptomatic, symptomatic patients commonly report epigastric pain, early satiety, bloating, nausea, belching, and halitosis; severe complications such as gastrointestinal bleeding, perforation, or obstruction may arise from untreated ulcers. Importantly, H. pylori infection significantly impairs quality of life—not only through physical discomfort and dietary restrictions but also via anxiety related to cancer risk, recurrent symptoms, treatment side effects (e.g., antibiotic-associated diarrhea, taste disturbances), and work absenteeism. Psychological burden—including health-related worry and reduced social engagement—is increasingly recognized in longitudinal studies. Early diagnosis—via non-invasive tests (urea breath test, stool antigen assay, serology) or invasive methods (rapid urease test, histology, culture during endoscopy)—is critical for timely eradication and prevention of long-term sequelae. Given rising global antimicrobial resistance—especially to clarithromycin, metronidazole, and levofloxacin—treatment must be tailored regionally and guided by susceptibility testing where available.

Helicobacter pylori (H. pylori) infection is a common bacterial colonization of the gastric mucosa, implicated in chronic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma. Management requires eradication therapy to prevent complications and recurrence. Treatment strategies are stratified into conservative (pharmacologic) approaches, surgical interventions (rarely indicated), and comprehensive recovery support. In China, national guidelines—such as those issued by the Chinese Society of Gastroenterology (CSG) and the Chinese Medical Association—are rigorously evidence-based, incorporating regional antibiotic resistance patterns and real-world clinical outcomes.

Conservative treatment remains the cornerstone of H. pylori management. First-line regimens emphasize high-eradication efficacy (>90%), tolerability, and adherence. The current standard in China is bismuth-containing quadruple therapy (BQT), recommended for 10–14 days: a proton pump inhibitor (PPI) (e.g., esomeprazole 20 mg or rabeprazole 10 mg twice daily), bismuth subcitrate potassium 220 mg twice daily, tetracycline 500 mg four times daily, and metronidazole 400 mg three or four times daily. This regimen achieves >92% eradication in regions with high clarithromycin resistance (>15%), which is prevalent across much of China. Alternative first-line options include concomitant therapy (PPI + amoxicillin + clarithromycin + metronidazole for 10–14 days) or hybrid therapy (sequential initiation with amoxicillin/PPI for 5 days, followed by PPI + amoxicillin + clarithromycin + metronidazole for 5 days), though BQT is preferred due to superior efficacy and lower resistance-driven failure. Second-line therapy is guided by antimicrobial susceptibility testing when available; otherwise, levofloxacin-based triple therapy (PPI + amoxicillin + levofloxacin) or rifabutin-based regimens may be used after failure of initial BQT. All regimens require strict adherence—missed doses significantly reduce eradication rates. Pharmacokinetic considerations are critical: PPIs must be dosed twice daily at optimal pH to maximize antibiotic stability (e.g., amoxicillin degrades rapidly in acidic environments), and bismuth enhances mucosal barrier function while exerting direct antibacterial effects.

Surgical treatment is not indicated for uncomplicated H. pylori infection. Surgery plays a strictly limited role and is reserved for rare, severe complications unresponsive to medical therapy. These include refractory bleeding ulcers with hemodynamic instability despite endoscopic intervention and pharmacologic control; perforated peptic ulcers requiring emergency laparoscopic or open repair; or gastric outlet obstruction secondary to chronic scarring and stenosis. In cases of H. pylori–associated early gastric cancer or high-grade dysplasia, endoscopic submucosal dissection (ESD) or gastrectomy may be performed—but these address neoplastic transformation, not the infection itself. Importantly, surgical resection does not obviate the need for postoperative eradication therapy, as residual gastric mucosa remains susceptible to reinfection or metachronous lesions. Therefore, surgery is adjunctive—not curative—for H. pylori, and all patients undergoing gastric resection should receive confirmatory postoperative H. pylori testing and targeted eradication if positive.

Treatment advantages in China stem from integrated, guideline-driven care delivery. First, nationwide surveillance networks (e.g., the China Antimicrobial Resistance Surveillance System for H. pylori) continuously monitor regional resistance trends—particularly clarithromycin, metronidazole, and levofloxacin—enabling dynamic regimen selection. Second, China’s robust primary-to-tertiary healthcare referral system ensures timely access to gastroenterology specialists and standardized breath tests (13C-urea breath test), stool antigen assays, and endoscopic biopsies with rapid urease testing and histopathology. Third, cost-effective generic formulations of bismuth compounds, tetracyclines, and PPIs are widely subsidized under the National Reimbursement Drug List, improving adherence in low-income populations. Fourth, digital health platforms (e.g., WeDoctor, Ping An Good Doctor) facilitate medication reminders, symptom diaries, and teleconsultations—proven to improve 14-day adherence by 27% in multicenter trials. Finally, China’s large-scale prospective registries (e.g., the China H. pylori Eradication Registry) generate real-world effectiveness data that directly inform iterative guideline updates—demonstrating sustained >90% eradication with optimized BQT protocols across diverse geographic and socioeconomic cohorts.

Recovery advice emphasizes both physiological healing and long-term prevention. Patients must complete the full antibiotic course—even if symptoms resolve early—to prevent selection of resistant strains. Symptom relief (e.g., epigastric pain, bloating) typically begins within 3–5 days but does not indicate eradication. Confirmatory testing is mandatory 4 weeks after therapy completion and ≥2 weeks after discontinuing PPIs (to avoid false-negative results); the 13C-urea breath test is preferred for its high sensitivity (95%) and specificity (98%). Lifestyle modifications support mucosal recovery: avoidance of NSAIDs, aspirin, alcohol, and tobacco; consumption of small, frequent meals; and restriction of highly spiced, acidic, or fried foods during active treatment. Probiotic supplementation (e.g., Lactobacillus reuteri DSM17648 or Saccharomyces boulardii CNCM I-745) may reduce antibiotic-associated diarrhea and improve eradication rates by 5–10%, though strain-specific evidence is required. Long-term follow-up includes annual symptom assessment and repeat testing only if new ulcer symptoms, unexplained iron-deficiency anemia, or alarm features (e.g., weight loss, vomiting, hematemesis) emerge. Family screening is advised in high-prevalence households, given fecal-oral and oral-oral transmission risks. Finally, dietary patterns rich in cruciferous vegetables (sulforaphane), green tea polyphenols, and fermented foods may confer adjunctive anti-H. pylori activity, though they are not substitutes for pharmacotherapy. With structured, guideline-adherent care, >95% of patients achieve durable eradication, significantly reducing lifetime risk of gastric malignancy and recurrent ulceration.